Bangalore (Karnataka) [India]: CryoVault Biotech India, headquartered in Bangalore, proudly commemorates nine years of transformative and affordable healthcare solutions. As an award-winning company, CryoVault Biotech India is dedicated to making biotech stem cell banking accessible to families across India, ensuring that hope is within reach for all, regardless of financial constraints.

Kolkata, West Bengal – Disha Eye Hospitals, a leader in ophthalmic care and innovation, is thrilled to announce significant advancements in the iStent Inject technology. This groundbreaking development is set to revolutionize the treatment of glaucoma, a leading cause of irreversible blindness globally. Committed to enhancing patient outcomes and quality of life, Disha Eye Hospitals remains at the forefront of introducing cutting-edge medical technologies.

Revolutionizing Glaucoma Treatment

Glaucoma affects millions of people worldwide, leading to gradual vision loss due to increased intraocular pressure (IOP). Traditional treatments often involve the prolonged use of eye drops or invasive surgeries, both of which can be burdensome and carry significant risks. The iStent Inject, a micro-invasive glaucoma surgery (MIGS) device, offers a minimally invasive alternative that effectively reduces IOP, providing a more manageable solution for glaucoma patients.

Advancements in iStent Inject Technology

The latest advancements in iStent Inject technology incorporate several key improvements:

1. Enhanced Biocompatibility: iStent Inject is crafted from advanced materials that are biocompatible, reducing the risk of adverse reactions and improving long-term patient outcomes.
2. Optimized Design: The redesigned stent features a smaller size and an ergonomic shape, allowing for easier implantation and better integration with the eye’s natural anatomy.
3. Improved Efficacy: Clinical trials have demonstrated that the iStent Inject significantly lowers IOP more consistently compared to previous models, offering patients reliable solution for managing their glaucoma.
4. Simplified Procedure: The implantation process has been refined to be even less invasive, shortening recovery times and reducing the overall risk of complications.

Advantages for Patients

The iStent Inject technology provides several advantages for patients, making it a superior choice for glaucoma treatment:

• Painless and Sutureless: The procedure is minimally invasive, causing minimal discomfort to patients. It does not require sutures, resulting in a quicker, more comfortable recovery.
• Combined with Cataract Surgery: The iStent Inject can be conveniently implanted during cataract surgery, allowing patients to address both conditions simultaneously. This combination reduces the number of surgical procedures and recovery periods.
• Micro Incision: The device is implanted through a micro incision, minimizing trauma to the eye and significantly reducing recovery time.
• Insurance and Cashless Facility: The iStent Inject procedure is covered under many insurance plans, offering patients the convenience of cashless treatment options at Disha Eye Hospitals. This makes advanced glaucoma care accessible and affordable.

Clinical Success and Patient Impact

The advancements in iStent Inject technology have been validated by extensive clinical research. Recent studies reveal that patients experience a marked reduction in IOP, leading to a decreased need for additional medications and a lower risk of glaucoma progression. Moreover, the simplified procedure has made it accessible to a broader range of patients, including those who may not be candidates for more invasive surgeries.

Expert Endorsements

Dr. Dipanjan Pal, a leading ophthalmologist at Disha Eye Hospitals, shared his insights: “The advancements in iStent Inject technology represent a significant leap forward in our ability to treat glaucoma effectively. This minimally invasive device offers our patients a safer, more efficient option to manage their condition and preserve their vision and minimises need for multiple topical antiglaucoma medicines. The biocompatibility and improved design have translated into better patient outcomes and a smoother recovery process.”

Dr. Arijit Mitra, another esteemed ophthalmic surgeon at Disha Eye Hospitals, echoed these sentiments: “We have seen remarkable results with the 2^nd Gen iStent Inject. Our patients report a substantial improvement in their quality of life due to the reduced dependency on daily eye drops and the minimized risk of complications associated with traditional surgeries. This technology truly embodies the future of glaucoma treatment.”

Dr. Suchanda Sar, one of the renowned Glaucoma Surgeon at Disha Eye Hospital said “This innovative tiny device will definitely help a class of patients in management of their glaucoma.”

About Disha Eye Hospitals

Disha Eye Hospitals is dedicated to pioneering innovative solutions in ophthalmology. With a commitment to excellence and a focus on improving patient care, we continue to lead the way in developing and implementing cutting-edge technologies that address the most pressing challenges in eye health. Our team of highly skilled and experienced ophthalmologists ensures that patients receive the best possible care with the most advanced treatments available.

For more information about the iStent Inject technology and our ongoing efforts to combat glaucoma, please visit Disha Eye Hospital.

About iStent Inject W

The iStent Inject W is a tiny implantable device designed to create a permanent pathway through the trabecular meshwork, improving aqueous humor outflow and lowering intraocular pressure in patients with glaucoma. It represents a significant advancement in minimally invasive glaucoma surgery, offering a safer and more effective treatment option.

Disha Eye Hospitals continues to be at the forefront of ophthalmic innovation, providing solutions that make a tangible difference in patients’ lives. The latest advancements in iStent Inject W technology underscore our commitment to excellence and our vision for a world where no one has to suffer from preventable blindness.

Empowering Communities with Mass Cardiac Screening and Early Detection using their Point of care ECG tool ‘SanketLife’

Noida, 19 June 2024 – Agatsa, a med-tech innovation company, is on a mission to mass screen the urban population for heart risks and underlying diseases by conducting Heart Health Camps in various RWA societies in the Delhi/NCR region. Their first camp in this initiative is the camp at the RWA Hyde Park in Sector 78, Noida, U.P., on Sunday, 16 June 2024. This marks the launch of Agatsa’s breakthrough campaign, “Har Ghar ECG,” aimed at heart health screening.

The “Har Ghar ECG” campaign is to empower patients, laypersons, and medical professionals to explore innovative tech devices and AI to not only screen and detect underlying cardiac diseases early but also to monitor and manage the diseases regularly for a fitter society and peace of mind. Agatsa’s pioneering Indian innovation, SanketLife, offers a miniature, pocket-sized, touch-based, fully medical-grade ECG device that transforms the traditional approach to heart disease alerts. With SanketLife, early detection of heart disease is possible, beyond the usual chest pain or other heart attack symptoms.

Rahul Rastogi, founder of Agatsa, quoted, “Agatsa’s aim, right from the beginning, has been saving people’s lives by promoting timely action before it’s too late. Traditionally, cardiac diseases are only detected when there is a severe symptom, and most people die during the first heart attack because they have ignored symptoms for too long. With our Har Ghar ECG Campaign, we aim to detect underlying cardiac problems with our device SanketLife save lives through timely action and intervention’ which works just by Touch. We seek support from various state governments to come forward and help us in our endeavor.”

Agatsa’s SanketLife provides instant ECG reports, with an option to receive a cardiologist’s opinion within 10 minutes. It is the world’s first leadless 12-lead ECG device, which is digital, connected, and easy to use, coupled with a mobile app. The device’s accessibility and convenience underscore the importance of early detection in managing heart conditions, potentially saving lives through timely medical intervention.

On the first day of the campaign, cardiac abnormalities were detected in residents of the society in Noida (Delhi/NCR). The patient was promptly advised and referred to a hospital for angiography and to begin treatment before it is too late. Hence, demonstrating the crucial role of early detection and life-saving intervention in cardiac cases, Agatsa aims to make preventive healthcare a household need, and Agatsa devices solve the purpose beautifully.

This initiative is launched in collaboration with Fortis Hospital with a well-known cardiologist present not just to raise awareness and disseminate knowledge but also to detect abnormalities and advise people on the right treatment.

The Heart Health Camp will feature screenings for ECG and stress levels using Agatsa’s advanced devices. Additionally, there will be cardiac consultations and an awareness talk led by Dr. Sanjeev Gera, Director of Cardiology at Fortis Hospital, Noida, alongside Dr. Hemant.

The camp commenced at 9:30 AM in the Club Area of Hyde Park, Sector 78, Noida, U.P., on Sunday, 16 June 2024.

Agatsa invites everyone to join and learn more about heart health and the critical benefits of early detection. If you also want to conduct such camps in your neighborhood, please contact Shantanu Singh at +91 94157 87209.

About Agatsa:

Agatsa, a MedTech Company founded by Rahul Rastogi and Neha Rastogi, is committed towards healthcare by providing top-quality services for all. Specializing in preventing cardiac diseases through early detection of behavioral risk factors, Agatsa emphasizes timely intervention and treatment. Its AI and IoT-driven platform, “SanketLife,”facilitates rapid assessment of cardiac health, bridging the gap between patients and healthcare providers.

Agatsa envisions a healthier world by offering effective digital healthcare solutions globally, particularly in cardiac health, to improve lives and eliminate stigmas surrounding overall health. The company’s mission is to revolutionize healthcare through technology, promoting health and wellness with quality monitoring devices. Founded in 2014 by Neha and Rahul Rastogi, Agatsa emerged from a desire to combat health risks and save lives. Rahul Rastogi and Neha Rastogi, with 14 years of experience, are dedicated to raising awareness about cardiac care and healthy living. Together, they embody Agatsa’s core values of excellence, teamwork, and inclusion shape the company’s purpose and guide its actions, evident in their revolutionary innovation of Agatsa’s SanketLife ECG and ongoing research for further innovative devices.